Drugs / WT-1 analog peptide vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00398138 | Oct 2006 → Jun 2009 | leukemia, lung cancer, malignant mesothelioma, myelodysplastic syndrome +1 | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT-1 analog peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00398138 ↗ |
| Known as | polyvalent WT1 peptide vaccine | “These preliminary data suggest that this polyvalent WT1 peptide vaccine can be administered safely to patients with a resulting immune response.” PMID 20400682 ↗ Apr 2010 |
| Modality | Vaccine | “polyvalent Wilms tumor gene 1 (WT1) peptide vaccine” PMID 20400682 ↗ Apr 2010 |
| Route | Subcutaneous | “Vaccinations will be administered subcutaneously” NCT00398138 ↗ |
| Target | WT1 | “polyvalent Wilms tumor gene 1 (WT1) peptide vaccine” PMID 20400682 ↗ Apr 2010 |